Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention

References

• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322. doi:10.1136/annrheumdis-2013-204627
   PubMed Web of Science ®Google Scholar
• Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78(11):1463–1471. doi:10.1136/annrheumdis-2019-215920
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi:10.1002/art.41752
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022;82(1):3–18. doi:10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386. doi:10.1056/NEJMoa1310476
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. doi:10.1056/NEJMoa1109071
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and Adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–468. doi:10.1016/S0140-6736(17)31618-5
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774. doi:10.1007/s12325-018-0805-y
   PubMed Web of Science ®Google Scholar
• Caporali R, Zavaglia D. Real-world experience with tofacitinib for treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2018;37(3):485–495.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. XELJANZ® (tofacitinib): highlights of prescribing information; 2022. Available from: https://labeling.pfizer.com/showlabeling.aspx?id=959. Accessed February 26, 2024.
   Google Scholar
• European Medicines Agency. XELJANZ® (tofacitinib): summary of product characteristics; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf. Accessed February 26, 2024.
   Google Scholar
• Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. doi:10.1186/s13075-019-1866-2
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18(1):34. doi:10.1186/s13075-016-0932-2
   PubMedGoogle Scholar
• Harnett J, Curtis JR, Gerber R, Gruben D, Koenig A. Initial experience with tofacitinib in clinical practice: treatment patterns and costs of tofacitinib administered as monotherapy or in combination with conventional synthetic DMARDs in 2 US health care claims databases. Clin Ther. 2016;38(6):1451–1463. doi:10.1016/j.clinthera.2016.03.038
   PubMed Web of Science ®Google Scholar
• Reed GW, Gerber RA, Shan Y, et al. Real-world comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019;6(4):573–586. doi:10.1007/s40744-019-00177-4
   PubMed Web of Science ®Google Scholar
• Bird P, Littlejohn G, Butcher B, et al. Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia. Clin Rheumatol. 2022;41(1):53–62. doi:10.1007/s10067-021-05853-x
   PubMed Web of Science ®Google Scholar
• Movahedi M, Choquette D, Coupal L, et al. Discontinuation rate of tofacitinib as monotherapy is similar compared to combination therapy with methotrexate in rheumatoid arthritis patients: pooled data from two rheumatoid arthritis registries in Canada [abstract]. Arthritis Rheumatol. 2021;73(suppl 10):0827.
   Google Scholar
• Movahedi M, Cesta A, Li X, Keystone E, Bombardier C. Time to discontinuation of tofacitinib and TNF inhibitors in rheumatoid arthritis patients with and without methotrexate: real world results from a rheumatoid arthritis cohort [abstract]. Arthritis Rheumatol. 2020;72(suppl 10):831.
   Google Scholar
• Gaujoux-Viala C, Basch A, Lassoued S, et al. Real word experience with tofacitinib in patients with rheumatoid arthritis: an interim analysis from a French prospective observational study DeFacTo [abstract]. Ann Rheum Dis. 2021;80(Suppl 1):POS0659. doi:10.1136/annrheumdis-2021-eular.870
   Google Scholar
• Rojas Zuleta WG, Felipe Diaz OJ, Giraldo Herrera CL, et al. Therapy with tofacitinib in a Colombian population with rheumatoid arthritis: results of the daily clinical practice [abstract]. Ann Rheum Dis. 2019;78:AB0441.
   Web of Science ®Google Scholar
• Kavanaugh A, Reed GW, Saunders KC, et al. Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United States after Food and Drug Administration approval: results from the Corrona US Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2014;66(suppl 10):1537. doi:10.1002/art.38378
   PubMedGoogle Scholar
• Bilgin E, Ceylan F, Duran E, et al. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turk J Med Sci. 2021;51(1):297–308. doi:10.3906/sag-2007-123
   PubMed Web of Science ®Google Scholar
• Finckh A, Tellenbach C, Herzog L, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020;6(1):e001174. doi:10.1136/rmdopen-2020-001174
   PubMed Web of Science ®Google Scholar
• Mueller RB, Hasler C, Popp F, et al. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med. 2019;8(10):1548. doi:10.3390/jcm8101548
   PubMed Web of Science ®Google Scholar
• Choquette D, Bessette L, Choquette Sauvageau L, et al. Tofacitinib monotherapy or combined with methotrexate in patients with rheumatoid arthritis show similar retention over four years. Report from Rhumadata® [abstract]. Ann Rheum Dis. 2020;79(suppl 1):AB0337. doi:10.1136/annrheumdis-2020-eular.2479
   Google Scholar
• Kivitz AJ, Cohen S, Keystone E, et al. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a phase 3 rheumatoid arthritis population. Semin Arthritis Rheum. 2018;48(3):406–415. doi:10.1016/j.semarthrit.2018.07.006
   PubMed Web of Science ®Google Scholar
• Pope J, Bessette L, Jones N, et al. Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology. 2020;59(3):568–574. doi:10.1093/rheumatology/kez324
   PubMed Web of Science ®Google Scholar
• González Mazarío R, Fragío Gil JJ, Ivorra Cortés J, et al. Real-world effectiveness and safety of JAK inhibitors in rheumatoid arthritis: a single-centre study. Reumatol Clin. 2022;18(9):523–530. doi:10.1016/j.reuma.2021.08.001
   PubMed Web of Science ®Google Scholar
• Navarro F, Martinez-Sesmero JM, Balsa A, et al. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol. 2020;39(10):2919–2930. doi:10.1007/s10067-020-05087-3
   PubMed Web of Science ®Google Scholar
• Claxton L, Taylor M, Soonasra A, Bourret JA, Gerber RA. An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. payer perspective. J Manag Care Spec Pharm. 2018;24(10):1010–1017. doi:10.18553/jmcp.2018.17220
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Wollenhaupt J, Cohen S, et al. Effect of discontinuation or initiation of methotrexate or glucocorticoids on tofacitinib efficacy in patients with rheumatoid arthritis: a post hoc analysis. Rheumatol Ther. 2018;5(1):203–214. doi:10.1007/s40744-018-0093-7
   PubMed Web of Science ®Google Scholar
• Cohen SB, Pope J, Haraoui B, et al. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. Lancet Rheumatol. 2019;1(1):E23–E34. doi:10.1016/S2665-9913(19)30005-0
   PubMedGoogle Scholar